(Reuters) – GSK said on Friday the addition of its cancer drug Jemperli to both standard of care chemotherapy and Zejula maintenance improved survival in patients with advanced ovarian cancer without the disease getting worse in a late-stage trial.
The British drugmaker, however, said that the trial failed to meet statistical significance in improving overall survival as a key secondary endpoint.
(Reporting by Aby Jose Koilparambil and Yadarisa Shabong in Bengaluru)
